Translating Data
into Discoveries

Phenomics-driven drug discovery for better translation of human biology

Currently, 90 percent of clinical trials fail before a drug can make it to patients. Data is siloed, the process is inefficient, and biology is inherently complex leading to a lack of clinical translation.

To better address this complexity, BioSymetrics takes a phenomics-driven approach to drug discovery. We integrate longitudinal, real-world patient data and experimental data, using machine learning, to translate human biology into medicines.

In other words: we apply human data to human disease. Our ultimate aim is to advance precision medicines for the many patients in need of a better standard of care.

Massive and dynamic data backed by diverse and strategic partners

We partner with global pharmaceutical companies, the nation’s top hospitals and health networks, and leading genomics and research organizations, to advance their disease research and drug discovery efforts and enhance our growing and diverse dataset. Today we integrate over 13 million longitudinal patient records - 100 million years worth of patient data - into our platform.

Drug discovery programs in neuroscience, cardiology and rare disorders

We are advancing a robust pipeline of early drug discovery programs in multi gene diseases where a target-based, reductionist view limits our disease understanding and decreases the chances of meaningful clinical translation to drug.

We are primarily focused on neurodegenerative, cardiac and rare disorders. Our lead drug discovery program is in atherosclerosis, a serious and potentially fatal, chronic inflammatory disease for which there is currently no treatment for the underlying cause.